Monoclonal antibodyFDA-approvedInvestigational
Sacituzumab Govitecan
How it works
Delivers a chemotherapy agent directly to cancer cells, causing cell death and preventing growth.
Cancer types
Breast Cancer— All patients
Ovarian Cancer— All patients
Efficacy
In clinical trials, around 35% of patients achieved an objective response, with median overall survival of approximately 11 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Combining Treatments May Help Fight Aggressive Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Testing Sacituzumab Govitecan and Cisplatin in Ovarian and Endometrial Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Testing Sacituzumab Govitecan in Advanced Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| New Study Examines Cancer Treatment in Lung Cancer Cells | Lung Cancer | lab-study | — | Source → |
| New Insights into Cancer Treatment with Sacituzumab Govitecan | Lung Cancer | phase-3 | Median overall survival with sacituzumab govitecan versus docetaxel was 8.9 versus 9.8 months (hazard ratio [HR] = 0.96, 95% CI: 0.68-1.38) and 11.8 versus 10.7 months (HR = 0.89, 95% CI: 0.60-1.32) in subgroups with Trop-2 histological scores greater than or equal to the median and less than the median, respectively. | Source → |
| Testing New Treatments for Metastatic Triple-Negative Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Testing a New Treatment for Advanced Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing a Combination Therapy for Early-stage Triple-negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing Sacituzumab Govitecan for Mesothelioma Treatment | Lung Cancer | phase-2 | — | Source → |
| Study of New Treatments for Triple Negative Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Lung Cancer Treatment Trial for Patients with Residual Disease | Lung Cancer | phase-3 | — | Source → |
| Testing Atezolizumab and Sacituzumab Govitecan to Prevent Triple Negative Breast Cancer Recurrence | Breast Cancer | phase-2 | — | Source → |
| Testing Alpelisib and Sacituzumab Govitecan for Breast Cancer Treatment | Breast Cancer | phase-1 | — | Source → |
| Study Examines Side Effects of Cancer Treatment in Advanced Breast Cancer Patients | Breast Cancer | observational | — | Source → |
| Testing Treatments for Advanced Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing a New Combination Treatment for Certain Cancers | Lung Cancer | phase-1 | — | Source → |
| Sacituzumab Govitecan and Radiation Therapy Treat Choroidal Metastases in Triple Negative Breast Cancer | Breast Cancer | observational | — | Source → |
| Sacituzumab govitecan shows promise in rare breast cancer subtype | Breast Cancer | observational | The overall response rate was 36.4%, clinical benefit rate 45.5%, median progression-free survival 3.2 months and median overall survival 8.9 months. | Source → |
| Researchers Study How Cancer Drug Works in Breast Cancer Patients | Breast Cancer | phase-3 | — | Source → |
| Expert Consensus on Managing Side Effects of New Cancer Treatment | Breast Cancer | review | — | Source → |
| New Options for Treating Advanced Breast Cancer | Breast Cancer | review | — | Source → |
| Gene Mutation Affects Safety of Cancer Treatment | Breast Cancer | review | — | Source → |
| New Study Examines Effectiveness and Safety of Cancer Treatment in Triple-Negative Breast Cancer Patients | Breast Cancer | phase-1/2 | The model-predicted proportions of patients with complete response and objective response rate were 4.26% and 32.6%, respectively. | Source → |
| New Cancer Treatment Cost-Effectiveness Study in China | Breast Cancer | phase-3 | Sacituzumab govitecan provided an additional 0.25 QALYs and an incremental cost of $ 81,778.61 compared with chemotherapy. | Source → |
| New Treatment Options for HER2-low Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| New Treatment Shows Promise for Advanced Breast Cancer | Breast Cancer | phase-3 | The primary end point was met with a 34% reduction in risk of progression or death. | Source → |
| New Treatment Shows Promise for Metastatic Triple-Negative Breast Cancer | Breast Cancer | phase-3 | Tumors shrank in more patients who took Sacituzumab Govitecan than in patients who took chemotherapy. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.